Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to the eventual death of motor neurons. Described cases of familial ALS have emphasized the significance of protein misfolding and aggregation of two functionally related proteins, FUS (fused in sarcoma) and TDP-43, implicated in RNA metabolism. Herein, we performed a comprehensive analysis of the in vivo model of FUS-mediated proteinopathy (ΔFUS(1-359) mice). First, we used the Noldus CatWalk system and confocal microscopy to determine the time of onset of the first clinical symptoms and the appearance of FUS-positive inclusions in the cytoplasm of neuronal cells. Second, we applied RNA-seq to evaluate changes in the gene expression profile encompassing the pre-symptomatic and the symptomatic stages of disease progression in motor neurons and the surrounding microglia of the spinal cord. The resulting data show that FUS-mediated proteinopathy is virtually asymptomatic in terms of both the clinical symptoms and the molecular aspects of neurodegeneration until it reaches the terminal stage of disease progression (120 days from birth). After this time, the pathological process develops very rapidly, resulting in the formation of massive FUS-positive inclusions accompanied by a transcriptional “burst” in the spinal cord cells. Specifically, it manifests in activation of a pro-inflammatory phenotype of microglial cells and malfunction of acetylcholine synapse transmission in motor neurons. Overall, we assume that the highly reproducible course of the pathological process, as well as the described accompanying features, makes ΔFUS(1-359) mice a convenient model for testing potential therapeutics against proteinopathy-induced decay of motor neurons.
Similar content being viewed by others
References
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071. https://doi.org/10.1038/nrdp.2017.71
Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A (2015) A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 6:171. https://doi.org/10.4103/2152-7806.169561
Hart PJ (2006) Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr Opin Chem Biol 10(2):131–138. https://doi.org/10.1016/j.cbpa.2006.02.034
Neumann LM, El Ghouzzi V, Paupe V, Weber HP, Fastnacht E, Leenen A, Lyding S, Klusmann A, Mayatepek E, Pelz J, Cormier-Daire V (2006) Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia: clinical and molecular findings in three families supporting genetic heterogeneity in Smith-McCort dysplasia. Am J Med Genet A 140(5):421–426. https://doi.org/10.1002/ajmg.a.31090
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870):1668–1672. https://doi.org/10.1126/science.1154584
Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323(5918):1208–1211. https://doi.org/10.1126/science.1165942
Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mora G, Sabatelli M, Monsurro MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G, Consortium I, Galassi G, Scholz SW, Taylor JP, Restagno G, Chio A, Traynor BJ (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68(5):857–864. https://doi.org/10.1016/j.neuron.2010.11.036
Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465(7295):223–226. https://doi.org/10.1038/nature08971
Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M, Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR, Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA, Siddique T (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477(7363):211–215. https://doi.org/10.1038/nature10353
Shang Y, Huang EJ (2016) Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res 1647:65–78. https://doi.org/10.1016/j.brainres.2016.03.036
Peters OM, Ghasemi M, Brown RH Jr (2015) Emerging mechanisms of molecular pathology in ALS. J Clin Invest 125(6):2548. https://doi.org/10.1172/JCI82693
Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, Schellenberg GD (2010) Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol 119(4):409–419. https://doi.org/10.1007/s00401-010-0659-0
Kuroda M, Sok J, Webb L, Baechtold H, Urano F, Yin Y, Chung P, de Rooij DG, Akhmedov A, Ashley T, Ron D (2000) Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. EMBO J 19(3):453–462. https://doi.org/10.1093/emboj/19.3.453
Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, Klewes L, Arapovic D, White EK, Koury MJ, Oltz EM, Van Kaer L, Ruley HE (2000) Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 24(2):175–179. https://doi.org/10.1038/72842
Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118(5):605–616. https://doi.org/10.1007/s00401-009-0581-5
Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132(Pt 11):2922–2931. https://doi.org/10.1093/brain/awp214
Scekic-Zahirovic J, Sendscheid O, El Oussini H, Jambeau M, Sun Y, Mersmann S, Wagner M, Dieterle S, Sinniger J, Dirrig-Grosch S, Drenner K, Birling MC, Qiu J, Zhou Y, Li H, Fu XD, Rouaux C, Shelkovnikova T, Witting A, Ludolph AC, Kiefer F, Storkebaum E, Lagier-Tourenne C, Dupuis L (2016) Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J 35(10):1077–1097. https://doi.org/10.15252/embj.201592559
Orsini M, Oliveira AB, Nascimento OJ, Reis CH, Leite MA, de Souza JA, Pupe C, de Souza OG, Bastos VH, de Freitas MR, Teixeira S, Bruno C, Davidovich E, Smidt B (2015) Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int 7(2):5885. https://doi.org/10.4081/ni.2015.5885
Farrawell NE, Lambert-Smith IA, Warraich ST, Blair IP, Saunders DN, Hatters DM, Yerbury JJ (2015) Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci Rep 5:13416. https://doi.org/10.1038/srep13416
Weisberg SJ, Lyakhovetsky R, Werdiger AC, Gitler AD, Soen Y, Kaganovich D (2012) Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity. Proc Natl Acad Sci USA 109(39):15811–15816. https://doi.org/10.1073/pnas.1205829109
Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 67(6):739–748. https://doi.org/10.1002/ana.22051
Yang W, Leystra-Lantz C, Strong MJ (2008) Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res 1196:131–139. https://doi.org/10.1016/j.brainres.2007.12.031
Kaganovich D, Kopito R, Frydman J (2008) Misfolded proteins partition between two distinct quality control compartments. Nature 454(7208):1088–1095. https://doi.org/10.1038/nature07195
Philips T, Rothstein JD (2015) Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol 69:5.67.1–21. https://doi.org/10.1002/0471141755.ph0567s69
Ahmed RM, Irish M, van Eersel J, Ittner A, Ke YD, Volkerling A, van der Hoven J, Tanaka K, Karl T, Kassiou M, Kril JJ, Piguet O, Gotz J, Kiernan MC, Halliday GM, Hodges JR, Ittner LM (2017) Mouse models of frontotemporal dementia: a comparison of phenotypes with clinical symptomatology. Neurosci Biobehav Rev 74(Pt A):126–138. https://doi.org/10.1016/j.neubiorev.2017.01.004
McGoldrick P, Joyce PI, Fisher EM, Greensmith L (2013) Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1832(9):1421–1436. https://doi.org/10.1016/j.bbadis.2013.03.012
Van Damme P, Robberecht W, Van Den Bosch L (2017) Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 10(5):537–549. https://doi.org/10.1242/dmm.029058
Murakami T, Yang SP, Xie L, Kawano T, Fu D, Mukai A, Bohm C, Chen F, Robertson J, Suzuki H, Tartaglia GG, Vendruscolo M, Kaminski Schierle GS, Chan FT, Moloney A, Crowther D, Kaminski CF, Zhen M, St George-Hyslop P (2012) ALS mutations in FUS cause neuronal dysfunction and death in Caenorhabditis elegans by a dominant gain-of-function mechanism. Hum Mol Genet 21(1):1–9. https://doi.org/10.1093/hmg/ddr417
Xia R, Liu Y, Yang L, Gal J, Zhu H, Jia J (2012) Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol Neurodegener 7:10. https://doi.org/10.1186/1750-1326-7-10
Huang C, Zhou H, Tong J, Chen H, Liu YJ, Wang D, Wei X, Xia XG (2011) FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet 7(3):e1002011. https://doi.org/10.1371/journal.pgen.1002011
Chen Y, Yang M, Deng J, Chen X, Ye Y, Zhu L, Liu J, Ye H, Shen Y, Li Y, Rao EJ, Fushimi K, Zhou X, Bigio EH, Mesulam M, Xu Q, Wu JY (2011) Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein Cell 2(6):477–486. https://doi.org/10.1007/s13238-011-1065-7
Devoy A, Kalmar B, Stewart M, Park H, Burke B, Noy SJ, Redhead Y, Humphrey J, Lo K, Jaeger J, Mejia Maza A, Sivakumar P, Bertolin C, Soraru G, Plagnol V, Greensmith L, Acevedo Arozena A, Isaacs AM, Davies B, Fratta P, Fisher EMC (2017) Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice. Brain J Neurol 140(11):2797–2805. https://doi.org/10.1093/brain/awx248
Shiihashi G, Ito D, Arai I, Kobayashi Y, Hayashi K, Otsuka S, Nakajima K, Yuzaki M, Itohara S, Suzuki N (2017) Dendritic homeostasis disruption in a novel frontotemporal dementia mouse model expressing cytoplasmic fused in sarcoma. EBioMedicine 24:102–115. https://doi.org/10.1016/j.ebiom.2017.09.005
Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Skvortsova VI, Ling SC, Da Cruz S, Parone PA, Buchman VL, Ninkina NN (2013) Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem 288(35):25266–25274. https://doi.org/10.1074/jbc.M113.492017
Anders S, Pyl PT, Huber W (2015) HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2):166–169. https://doi.org/10.1093/bioinformatics/btu638
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15–21. https://doi.org/10.1093/bioinformatics/bts635
Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30(15):2114–2120. https://doi.org/10.1093/bioinformatics/btu170
Krasnov GS, Dmitriev AA, Kudryavtseva AV, Shargunov AV, Karpov DS, Uroshlev LA, Melnikova NV, Blinov VM, Poverennaya EV, Archakov AI, Lisitsa AV, Ponomarenko EA (2015) PPLine: an automated pipeline for SNP, SAP, and splice variant detection in the context of proteogenomics. J Proteome Res 14(9):3729–3737. https://doi.org/10.1021/acs.jproteome.5b00490
Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1):139–140. https://doi.org/10.1093/bioinformatics/btp616
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing, vol 57. https://doi.org/10.2307/2346101
Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O’Keeffe S, Phatnani HP, Muratet M, Carroll MC, Levy S, Tavazoie S, Myers RM, Maniatis T (2013) A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 4(2):385–401. https://doi.org/10.1016/j.celrep.2013.06.018
Bandyopadhyay U, Cotney J, Nagy M, Oh S, Leng J, Mahajan M, Mane S, Fenton WA, Noonan JP, Horwich AL (2013) RNA-Seq profiling of spinal cord motor neurons from a presymptomatic SOD1 ALS mouse. PLoS One 8(1):e53575. https://doi.org/10.1371/journal.pone.0053575
Huang d W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57. https://doi.org/10.1038/nprot.2008.211
Mazin P, Xiong J, Liu X, Yan Z, Zhang X, Li M, He L, Somel M, Yuan Y, Phoebe Chen YP, Li N, Hu Y, Fu N, Ning Z, Zeng R, Yang H, Chen W, Gelfand M, Khaitovich P (2013) Widespread splicing changes in human brain development and aging. Mol Syst Biol 9:633. https://doi.org/10.1038/msb.2012.67
Young MD, Wakefield MJ, Smyth GK, Oshlack A (2010) Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol 11(2):R14. https://doi.org/10.1186/gb-2010-11-2-r14
Shelkovnikova TA, Robinson HK, Southcombe JA, Ninkina N, Buchman VL (2014) Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum Mol Genet 23(19):5211–5226. https://doi.org/10.1093/hmg/ddu243
Shelkovnikova TA, Robinson HK, Connor-Robson N, Buchman VL (2013) Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. Cell Cycle 12(19):3194–3202. https://doi.org/10.4161/cc.26241
Okano T, Sasaki M, Fukada Y (2001) Cloning of mouse BMAL2 and its daily expression profile in the suprachiasmatic nucleus: a remarkable acceleration of Bmal2 sequence divergence after BMAL gene duplication. Neurosci Lett 300(2):111–114
Costa MJ, Finkenstadt B, Roche V, Levi F, Gould PD, Foreman J, Halliday K, Hall A, Rand DA (2013) Inference on periodicity of circadian time series. Biostatistics 14(4):792–806. https://doi.org/10.1093/biostatistics/kxt020
Ding H, Liu S, Yuan Y, Lin Q, Chan P, Cai Y (2011) Decreased expression of Bmal2 in patients with Parkinson’s disease. Neurosci Lett 499(3):186–188. https://doi.org/10.1016/j.neulet.2011.05.058
Bosco P, Spada R, Caniglia S, Salluzzo MG, Salemi M (2014) Cerebellar degeneration-related autoantigen 1 (CDR1) gene expression in Alzheimer’s disease. Neurol Sci 35(10):1613–1614. https://doi.org/10.1007/s10072-014-1805-6
Zhou ZD, Sathiyamoorthy S, Tan EK (2012) LINGO-1 and neurodegeneration: pathophysiologic clues for essential tremor. Tremor Other Hyperkinet Mov 2. https://doi.org/10.7916/D8PZ57JV
Zhang Z, Xu X, Xiang Z, Yu Z, Feng J, He C (2013) LINGO-1 receptor promotes neuronal apoptosis by inhibiting WNK3 kinase activity. J Biol Chem 288(17):12152–12160. https://doi.org/10.1074/jbc.M112.447771
Sadri-Vakili G, Cha JH (2006) Histone deacetylase inhibitors: a novel therapeutic approach to Huntington’s disease (complex mechanism of neuronal death). Curr Alzheimer Res 3(4):403–408
Ryu JK, Kim SU, McLarnon JG (2003) Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington’s disease. Exp Neurol 183(2):700–704
Lee J, Hong YK, Jeon GS, Hwang YJ, Kim KY, Seong KH, Jung MK, Picketts DJ, Kowall NW, Cho KS, Ryu H (2012) ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington’s disease. Cell Death Differ 19(7):1109–1116. https://doi.org/10.1038/cdd.2011.196
Phatnani HP, Guarnieri P, Friedman BA, Carrasco MA, Muratet M, O’Keeffe S, Nwakeze C, Pauli-Behn F, Newberry KM, Meadows SK, Tapia JC, Myers RM, Maniatis T (2013) Intricate interplay between astrocytes and motor neurons in ALS. Proc Natl Acad Sci U S A 110(8):E756–E765. https://doi.org/10.1073/pnas.1222361110
MacKeigan JP, Murphy LO, Blenis J (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7(6):591–600. https://doi.org/10.1038/ncb1258
Qu Z, Zhang H, Huang M, Shi G, Liu Z, Xie P, Li H, Wang W, Xu G, Zhang Y, Yang L, Huang G, Takahashi JS, Zhang WJ, Xu Y (2016) Loss of ZBTB20 impairs circadian output and leads to unimodal behavioral rhythms. eLife 5. https://doi.org/10.7554/eLife.17171
Nagao M, Ogata T, Sawada Y, Gotoh Y (2016) Zbtb20 promotes astrocytogenesis during neocortical development. Nat Commun 7:11102. https://doi.org/10.1038/ncomms11102
Lee S, Shang Y, Redmond SA, Urisman A, Tang AA, Li KH, Burlingame AL, Pak RA, Jovicic A, Gitler AD, Wang J, Gray NS, Seeley WW, Siddique T, Bigio EH, Lee VM, Trojanowski JQ, Chan JR, Huang EJ (2016) Activation of HIPK2 promotes ER stress-mediated neurodegeneration in amyotrophic lateral sclerosis. Neuron 91(1):41–55. https://doi.org/10.1016/j.neuron.2016.05.021
Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D’Ambrosi N (2017) The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 9:242. https://doi.org/10.3389/fnagi.2017.00242
Thrash JC, Torbett BE, Carson MJ (2009) Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res 34(1):38–45. https://doi.org/10.1007/s11064-008-9657-1
Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, Stalder AK, Staufenbiel M, Neumann H, Carson MJ (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer’s disease. ASN Neuro 2(3):e00037. https://doi.org/10.1042/AN20100010
Krook A (2008) IL-6 and metabolism-new evidence and new questions. Diabetologia 51(7):1097–1099. https://doi.org/10.1007/s00125-008-1019-7
Palacz-Wrobel M, Borkowska P, Paul-Samojedny M, Kowalczyk M, Fila-Danilow A, Suchanek-Raif R, Kowalski J (2017) Effect of apigenin, kaempferol and resveratrol on the gene expression and protein secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) in RAW-264.7 macrophages. Biomed Pharmacother 93:1205–1212. https://doi.org/10.1016/j.biopha.2017.07.054
Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A (2014) A plural role for lipids in motor neuron diseases: energy, signaling and structure. Front Cell Neurosci 8:25. https://doi.org/10.3389/fncel.2014.00025
Miana-Mena FJ, Gonzalez-Mingot C, Larrode P, Munoz MJ, Olivan S, Fuentes-Broto L, Martinez-Ballarin E, Reiter RJ, Osta R, Garcia JJ (2011) Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis. J Neurol 258(5):762–769. https://doi.org/10.1007/s00415-010-5825-8
Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, Povedano M, Bellmunt MJ, Ferrer I, Pamplona R, Portero-Otin M (2007) Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 130(Pt 12):3111–3123. https://doi.org/10.1093/brain/awm190
Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J (2014) The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal 26(12):2694–2701. https://doi.org/10.1016/j.cellsig.2014.08.019
Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, Barmada SJ, Finkbeiner S, Lui H, Carlton CE, Tang AA, Oldham MC, Wang H, Shorter J, Filiano AJ, Roberson ED, Tourtellotte WG, Chen B, Tsai LH, Huang EJ (2014) ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest 124(3):981–999. https://doi.org/10.1172/JCI72723
Ederle H, Dormann D (2017) TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett 591(11):1489–1507. https://doi.org/10.1002/1873-3468.12646
Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao WW, Morrill K, Prazak L, Rozhkov N, Theodorou D, Hammell M, Dubnau J (2017) Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet 13(3):e1006635. https://doi.org/10.1371/journal.pgen.1006635
Amlie-Wolf A, Ryvkin P, Tong R, Dragomir I, Suh E, Xu Y, Van Deerlin VM, Gregory BD, Kwong LK, Trojanowski JQ, Lee VM, Wang LS, Lee EB (2015) Transcriptomic changes due to cytoplasmic TDP-43 expression reveal dysregulation of histone transcripts and nuclear chromatin. PLoS One 10(10):e0141836. https://doi.org/10.1371/journal.pone.0141836
Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14(4):459–468. https://doi.org/10.1038/nn.2779
Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, Quesnel-Vallieres M, Tapial J, Raj B, O’Hanlon D, Barrios-Rodiles M, Sternberg MJ, Cordes SP, Roth FP, Wrana JL, Geschwind DH, Blencowe BJ (2014) A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell 159(7):1511–1523. https://doi.org/10.1016/j.cell.2014.11.035
Marom A, Barak AF, Kramer MP, Lewinsky H, Binsky-Ehrenreich I, Cohen S, Tsitsou-Kampeli A, Kalchenko V, Kuznetsov Y, Mirkin V, Dezorella N, Shapiro M, Schwartzberg PL, Cohen Y, Shvidel L, Haran M, Becker-Herman S, Herishanu Y, Shachar I (2017) CD84 mediates CLL-microenvironment interactions. Oncogene 36(5):628–638. https://doi.org/10.1038/onc.2016.238
Nasti TH, Cochran JB, Vachhani RV, McKay K, Tsuruta Y, Athar M, Timares L, Elmets CA (2017) IL-23 inhibits melanoma development by augmenting DNA repair and modulating T cell subpopulations. J Immunol 198(2):950–961. https://doi.org/10.4049/jimmunol.1601455
Longtine MS, Cvitic S, Colvin BN, Chen B, Desoye G, Nelson DM (2017) Calcitriol regulates immune genes CD14 and CD180 to modulate LPS responses in human trophoblasts. Reproduction 154(6):735–744. https://doi.org/10.1530/REP-17-0183
Fontaine M, Vogel I, Van Eycke YR, Galuppo A, Ajouaou Y, Decaestecker C, Kassiotis G, Moser M, Leo O (2018) Regulatory T cells constrain the TCR repertoire of antigen-stimulated conventional CD4 T cells. EMBO J 37(3):398–412. https://doi.org/10.15252/embj.201796881
Kramer CD, Genco CA (2017) Microbiota, immune subversion, and chronic inflammation. Front Immunol 8:255. https://doi.org/10.3389/fimmu.2017.00255
Zuidscherwoude M, Worah K, van der Schaaf A, Buschow SI, van Spriel AB (2017) Differential expression of tetraspanin superfamily members in dendritic cell subsets. PLoS One 12(9):e0184317. https://doi.org/10.1371/journal.pone.0184317
Ambrose EC, Kornbluth J (2009) Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells. Apoptosis 14(10):1227–1236. https://doi.org/10.1007/s10495-009-0385-z
Dang AK, Tesfagiorgis Y, Jain RW, Craig HC, Kerfoot SM (2015) Meningeal infiltration of the spinal cord by non-classically activated B cells is associated with chronic disease course in a spontaneous B cell-dependent model of CNS autoimmune disease. Front Immunol 6:470. https://doi.org/10.3389/fimmu.2015.00470
Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, Wang Y, Zhong Z, Sullivan JS, Griffin JH, Cleveland DW, Zlokovic BV (2014) Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A 111(11):E1035–E1042. https://doi.org/10.1073/pnas.1401595111
Jones TB (2014) Lymphocytes and autoimmunity after spinal cord injury. Exp Neurol 258:78–90. https://doi.org/10.1016/j.expneurol.2014.03.003
Noristani HN, Sabourin JC, Gerber YN, Teigell M, Sommacal A, Vivanco M, Weber M, Perrin FE (2015) Brca1 is expressed in human microglia and is dysregulated in human and animal model of ALS. Mol Neurodegener 10(34):34. https://doi.org/10.1186/s13024-015-0023-x
Grujic M, Bartholdy C, Remy M, Pinschewer DD, Christensen JP, Thomsen AR (2010) The role of CD80/CD86 in generation and maintenance of functional virus-specific CD8+ T cells in mice infected with lymphocytic choriomeningitis virus. J Immunol 185(3):1730–1743. https://doi.org/10.4049/jimmunol.0903894
Nitschke L (2009) CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 230(1):128–143. https://doi.org/10.1111/j.1600-065X.2009.00801.x
Brandes M, Legler DF, Spoerri B, Schaerli P, Moser B (2000) Activation-dependent modulation of B lymphocyte migration to chemokines. Int Immunol 12(9):1285–1292
Seda V, Mraz M (2015) B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 94(3):193–205. https://doi.org/10.1111/ejh.12427
Koretzky GA, Abtahian F, Silverman MA (2006) SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol 6(1):67–78. https://doi.org/10.1038/nri1750
Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, McCampbell A, Leblanc G, Venkateswaran A, Nurmi A, Hodgson R (2017) Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener 6:6. https://doi.org/10.1186/s40035-017-0077-5
Renton AE, Chio A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17–23. https://doi.org/10.1038/nn.3584
Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 8:28. https://doi.org/10.1186/1750-1326-8-28
Julien JP, Kriz J (2006) Transgenic mouse models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762(11–12):1013–1024. https://doi.org/10.1016/j.bbadis.2006.03.006
Lobsiger CS, Boillee S, Cleveland DW (2007) Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A 104(18):7319–7326. https://doi.org/10.1073/pnas.0702230104
Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ (2007) Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci 27(34):9201–9219. https://doi.org/10.1523/JNEUROSCI.1470-07.2007
LaFlamme B (2015) Microexons on the brain. Nat Genet 47:105. https://doi.org/10.1038/ng.3207
Porter RS, Jaamour F, Iwase S (2018) Neuron-specific alternative splicing of transcriptional machineries: implications for neurodevelopmental disorders. Mol Cell Neurosci 87:35–45. https://doi.org/10.1016/j.mcn.2017.10.006
Luisier R, Tyzack GE, Hall CE, Mitchell JS, Devine H, Taha DM, Malik B, Meyer I, Greensmith L, Newcombe J, Ule J, Luscombe NM, Patani R (2018) Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat Commun 9(1):2010. https://doi.org/10.1038/s41467-018-04373-8
Sharma A, Lyashchenko AK, Lu L, Nasrabady SE, Elmaleh M, Mendelsohn M, Nemes A, Tapia JC, Mentis GZ, Shneider NA (2016) ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun 7:10465. https://doi.org/10.1038/ncomms10465
Dodge JC, Treleaven CM, Fidler JA, Tamsett TJ, Bao C, Searles M, Taksir TV, Misra K, Sidman RL, Cheng SH, Shihabuddin LS (2013) Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci U S A 110(26):10812–10817. https://doi.org/10.1073/pnas.1308421110
Shiihashi G, Ito D, Yagi T, Nihei Y, Ebine T, Suzuki N (2016) Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. Brain 139(Pt 9):2380–2394. https://doi.org/10.1093/brain/aww161
E Hirbec H, Noristani HN, Perrin FE (2017) Microglia responses in acute and chronic neurological diseases: what microglia-specific transcriptomic studies taught (and did not teach) us. Front Aging Neurosci 9:227. https://doi.org/10.3389/fnagi.2017.00227
Liao B, Zhao W, Beers DR, Henkel JS, Appel SH (2012) Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 237(1):147–152. https://doi.org/10.1016/j.expneurol.2012.06.011
Chio CC, Lin MT, Chang CP (2015) Microglial activation as a compelling target for treating acute traumatic brain injury. Curr Med Chem 22(6):759–770
Gravel M, Beland LC, Soucy G, Abdelhamid E, Rahimian R, Gravel C, Kriz J (2016) IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J Neurosci 36(3):1031–1048. https://doi.org/10.1523/JNEUROSCI.0854-15.2016
Macauley MS, Crocker PR, Paulson JC (2014) Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 14(10):653–666. https://doi.org/10.1038/nri3737
Linnartz-Gerlach B, Kopatz J, Neumann H (2014) Siglec functions of microglia. Glycobiology 24(9):794–799. https://doi.org/10.1093/glycob/cwu044
Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J (2004) Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 46(4):369–379. https://doi.org/10.1002/glia.20009
Acknowledgements
We thank Dr. Vladimir Buchman for critical comments on the manuscript. We are grateful to Vladimir Popenko for technical assistance with confocal microscopy and Tom Hurt for language improvements. We thank Nailia Khasbiullina from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS for many helpful recommendations on the interpretation of results. Facilities of the Bioresource Collection of IPAC RAS (No. 0090-2017-0016) were used to maintain animals for CatWalk data collection using equipment of the Center for Collective Use IPAC RAS. Transgenic animal research was carried out according to the State Research Program assignment for IPAC RAS (No. 0090-2017-0019). RNA sequencing was performed using the equipment of the Engelhardt Institute of Molecular Biology RAS “Genome” center (http://www.eimb.ru/rus/ckp/ccu_genome_c.php).
Funding
Life expectancy and immunohistochemical analysis studies were supported by the RFBR (№16-04-01089А). Transcriptome profile analysis was supported by the Russian Science Foundation (RSF) grant №14-50-00060. This work was supported by the Program of Fundamental Research for State Academies for the years 2013-2020 (№01201363817).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Supplemental figure S1
Multidimensional scaling (MDS) was performed using one minus the Spearman correlation coefficient between z-scores for all mice (WT are shown in green, ΔFUS(1-359) are in red). (PNG 227 kb)
Supplemental figure S2
Analysis of similarities and differences in gene expression profiles among the biological replicates of ΔFUS(1-359) and wild-type mice. A) Heatmap based on the pairwise Spearman correlation of gene expression with the use of the Euclidean distance and complete linkage as distance measures and clustering methods, respectively. B) Two-dimensional plot of the first two principal components calculated by PCA of the transposed log-transformed RPM values of gene expression. (PNG 233 kb)
Supplemental figure S3
Chemokine signaling pathway at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 30 kb)
Supplemental figure S4
NF-kB signaling pathway at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 45 kb)
Supplemental figure S5
Cell adhesion molecules at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 50 kb)
Supplemental figure S6
Antigen processing and presentation at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 22 kb)
Supplemental figure S7
Toll-like receptor signaling pathway at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 33 kb)
Supplemental figure S8
B cell receptor signaling pathway at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 23 kb)
Supplemental figure S9
Boxplot of Trem2 expression in the spinal cord of ΔFUS(1-359) mice. * indicates P ≤ 0.05. (PNG 67 kb)
Supplemental figure S10
Comparative analysis of ΔFUS(1-359) and SOD1G93A microglia transcriptome data. A) PCA-plot of FUS(1-359) and SOD1G93A microglia at the symptomatic stage (120 days for FUS(1-359) and 130 days for SOD1G93A) of disease progression. B) Heatmap on the top illustrates fold change of gene expression between the symptomatic and pre-symptomatic stages of ΔFUS(1-359) and SOD1G93A microglia. On the bottom the expression levels of genes at the terminal (symptomatic) stage are shown. Normalization type is counts per million (CPM). (PNG 1337 kb)
Supplemental figure S11
Steroid biosynthesis at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 28 kb)
Supplemental figure S12
Cholinergic synapse at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 38 kb)
Supplemental figure S13
Amyotrophic lateral sclerosis pathway at the symptomatic stage (120 days) of ΔFUS(1-359) mice based on KEGG analysis IDs, color-coded by expression level. (PNG 36 kb)
Supplemental figure S14
Changes in alternative splicing in the spinal cord of ΔFUS(1-359). A) MDS plot for all samples based on cassette exons (CE). Transgenic and wild-type mice are shown in red and green, respectively; different ages are shown by different point size. B) Number of statistically significant AS events for different pairwise comparisons; different AS event types are shown by different colors. Cassette exons (CE), alternative donor (AD) or alternative acceptor (AA) sites, and retained introns (RI). C) Correlation of dPSI between the asymptomatic (60 days) and the symptomatic (120 days) of ΔFUS(1-359) mice (x-axis) and dPSI between the symptomatic ΔFUS(1-359) mice and wild-type mice of the same age (120 days) (y-axis). Only events significant in both comparisons are shown. Different AS types are shown by different colors. D) Distribution of dPSI of significantly changes microexons (red, N = 62) and other exons (gray, N = 343). (PNG 408 kb)
Supplemental table S1
Differentially expressed genes in the spinal cord of ΔFUS(1-359) mice sorted by microglia, motoneurons and non-specific groups. (XLS 171 kb)
Supplemental table S2
GO analysis of genes exhibiting alternative splicing events at the symptomatic stage in the spinal cord of ΔFUS(1-359) mice. (XLS 20 kb)
Rights and permissions
About this article
Cite this article
Funikov, S.Y., Rezvykh, A.P., Mazin, P.V. et al. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy. Neurogenetics 19, 189–204 (2018). https://doi.org/10.1007/s10048-018-0553-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-018-0553-9